CN110857308A - 一种注射用头孢他啶的制备方法 - Google Patents
一种注射用头孢他啶的制备方法 Download PDFInfo
- Publication number
- CN110857308A CN110857308A CN201810975639.XA CN201810975639A CN110857308A CN 110857308 A CN110857308 A CN 110857308A CN 201810975639 A CN201810975639 A CN 201810975639A CN 110857308 A CN110857308 A CN 110857308A
- Authority
- CN
- China
- Prior art keywords
- ceftazidime
- solution
- solvent
- preparation
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000484 ceftazidime Drugs 0.000 title claims abstract description 155
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 title claims abstract description 155
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 238000002347 injection Methods 0.000 title claims abstract description 23
- 239000007924 injection Substances 0.000 title claims abstract description 23
- 239000000243 solution Substances 0.000 claims abstract description 78
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000012296 anti-solvent Substances 0.000 claims abstract description 23
- 238000001914 filtration Methods 0.000 claims abstract description 16
- 239000012043 crude product Substances 0.000 claims abstract description 12
- 239000000047 product Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000725 suspension Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000008215 water for injection Substances 0.000 claims abstract description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 7
- KGWHMDCQVDMTNZ-UHFFFAOYSA-N 2-(butylcarbamoylamino)acetic acid Chemical compound CCCCNC(=O)NCC(O)=O KGWHMDCQVDMTNZ-UHFFFAOYSA-N 0.000 description 6
- 229960003547 ceftazidime pentahydrate Drugs 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JLZLIGALAZXURA-ZYMGEXDGSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxylatopropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydron;dihydrochloride Chemical compound Cl.Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 JLZLIGALAZXURA-ZYMGEXDGSA-N 0.000 description 2
- -1 2-amino-4-thiazolyl Chemical group 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- OENLEHTYJXMVBG-UHFFFAOYSA-N pyridine;hydrate Chemical compound [OH-].C1=CC=[NH+]C=C1 OENLEHTYJXMVBG-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810975639.XA CN110857308B (zh) | 2018-08-24 | 2018-08-24 | 一种注射用头孢他啶的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810975639.XA CN110857308B (zh) | 2018-08-24 | 2018-08-24 | 一种注射用头孢他啶的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110857308A true CN110857308A (zh) | 2020-03-03 |
CN110857308B CN110857308B (zh) | 2021-02-26 |
Family
ID=69635777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810975639.XA Active CN110857308B (zh) | 2018-08-24 | 2018-08-24 | 一种注射用头孢他啶的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110857308B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111196818A (zh) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | 一种注射用头孢他啶的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769450A (en) * | 1984-03-09 | 1988-09-06 | Glaxo Group Limited | Process for recovering ceftazidime |
JPH07185335A (ja) * | 1993-12-28 | 1995-07-25 | Eisai Kagaku Kk | 合成吸着剤の洗浄方法及び洗浄された合成吸着剤 |
CN1775784A (zh) * | 2004-11-16 | 2006-05-24 | 广州白云山制药股份有限公司 | 头孢他啶的纯化方法 |
CN104666249A (zh) * | 2015-03-10 | 2015-06-03 | 华北制药河北华民药业有限责任公司 | 一种注射用头孢他啶粉针制剂 |
CN105560194A (zh) * | 2014-10-17 | 2016-05-11 | 广州艾奇西医药科技有限公司 | 高纯度的头孢他啶粉针剂及其制备方法 |
CN106317080A (zh) * | 2016-08-17 | 2017-01-11 | 陕西顿斯制药有限公司 | 一种采用耦合结晶技术制备的头孢他啶化合物及其制剂 |
-
2018
- 2018-08-24 CN CN201810975639.XA patent/CN110857308B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769450A (en) * | 1984-03-09 | 1988-09-06 | Glaxo Group Limited | Process for recovering ceftazidime |
JPH07185335A (ja) * | 1993-12-28 | 1995-07-25 | Eisai Kagaku Kk | 合成吸着剤の洗浄方法及び洗浄された合成吸着剤 |
CN1775784A (zh) * | 2004-11-16 | 2006-05-24 | 广州白云山制药股份有限公司 | 头孢他啶的纯化方法 |
CN105560194A (zh) * | 2014-10-17 | 2016-05-11 | 广州艾奇西医药科技有限公司 | 高纯度的头孢他啶粉针剂及其制备方法 |
CN104666249A (zh) * | 2015-03-10 | 2015-06-03 | 华北制药河北华民药业有限责任公司 | 一种注射用头孢他啶粉针制剂 |
CN106317080A (zh) * | 2016-08-17 | 2017-01-11 | 陕西顿斯制药有限公司 | 一种采用耦合结晶技术制备的头孢他啶化合物及其制剂 |
Non-Patent Citations (2)
Title |
---|
刘作华 等: "《流体混沌混合及搅拌过程强化方法》", 30 June 2016, 重庆大学出版社 * |
刘煜婷 等: ""头抱他咤五水化合物结晶工艺的改进"", 《黑龙江医药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111196818A (zh) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | 一种注射用头孢他啶的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110857308B (zh) | 2021-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1246831B1 (en) | Preparation method of azithromycin dihydrate | |
KR101929960B1 (ko) | 에르타페넴 나트륨의 결정형 및 이의 제조 방법 | |
RU2636939C2 (ru) | Способ получения тригидроксиэтилрутозида | |
CN106397456B (zh) | 一种含高纯度头孢地尼的组合物及其精制方法 | |
CN102993043B (zh) | 一种制备高纯度盐酸四环素的方法 | |
CN110857308B (zh) | 一种注射用头孢他啶的制备方法 | |
CN106892950B (zh) | 一种高含量曲克芦丁的制备方法 | |
WO2020156176A1 (zh) | 苯氧乙酸衍生物及利用其酶法制备青霉素v盐的方法 | |
CN111196818A (zh) | 一种注射用头孢他啶的制备方法 | |
CN106543025A (zh) | 一种高纯度盐酸多西环素的制备方法 | |
CN108690050B (zh) | 一种舒巴坦钠的纯化方法 | |
CN112625002A (zh) | 一种医药级二硫化二苯并噻唑的制备方法 | |
CN107793432B (zh) | 头孢曲松钠粗盐的精制方法 | |
CN114349772B (zh) | 一种比阿培南粗品的精制方法 | |
CN114874237A (zh) | 一种头孢噻肟钠的精制方法 | |
CN111718358B (zh) | 高流动性聚丙烯成核剂的制法 | |
CN114349768A (zh) | 一种头孢噻肟酸的制备方法 | |
CN110857307B (zh) | 一种注射用头孢呋辛钠的制备方法 | |
CN108707158B (zh) | 一种硫酸头孢匹罗的纯化方法 | |
US20140121369A1 (en) | Method for purifying ceftizoxime sodium | |
CN110804080B (zh) | 乙酰氨基阿维菌素晶型a、晶型b、非晶体及其制备方法 | |
CN102746324A (zh) | 一种盐酸头孢替安的纯化方法及盐酸头孢替安无菌粉针剂 | |
CN103102358A (zh) | 一种头孢类化合物、其晶体及其制备方法和用途 | |
CN111909180A (zh) | 稳定性好、可操作化高的头孢曲松钠晶体的制备方法 | |
CN114853786B (zh) | 一种头孢西丁钠粉体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of ceftazidime for injection Effective date of registration: 20210325 Granted publication date: 20210226 Pledgee: China Minsheng Banking Corp Hangzhou branch Pledgor: ZHEJIANG CHANGDIAN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021330000241 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210226 Pledgee: China Minsheng Banking Corp Hangzhou branch Pledgor: ZHEJIANG CHANGDIAN PHARMACEUTICAL CO.,LTD. Registration number: Y2021330000241 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240606 Address after: On the first floor of Building A-24, located one kilometer north of the South First Ring Road in the Old Town Development Zone of Chengmai County, Hainan Province, 571900 (Hainan Ecological Software Park) Patentee after: Gugor Pharmaceutical (Hainan) Co.,Ltd. Country or region after: China Address before: 310000 701, room 2, Tong CE square, 3688 Jiangnan Road, Binjiang District, Hangzhou, Zhejiang. Patentee before: ZHEJIANG CHANGDIAN PHARMACEUTICAL CO.,LTD. Country or region before: China |